Lees Pharmaceutical Holdings Stock Return On Equity
LPCUFDelisted Stock | USD 0.0001 0.00 0.00% |
Lees Pharmaceutical Holdings fundamentals help investors to digest information that contributes to Lees Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Lees Pink Sheet. The fundamental analysis module provides a way to measure Lees Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lees Pharmaceutical pink sheet.
Lees |
Lees Pharmaceutical Holdings Company Return On Equity Analysis
Lees Pharmaceutical's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Lees Pharmaceutical Return On Equity | -0.0531 |
Most of Lees Pharmaceutical's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lees Pharmaceutical Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Lees Pharmaceutical Holdings has a Return On Equity of -0.0531. This is 99.78% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on equity for all United States stocks is 82.87% lower than that of the firm.
Lees Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lees Pharmaceutical's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Lees Pharmaceutical could also be used in its relative valuation, which is a method of valuing Lees Pharmaceutical by comparing valuation metrics of similar companies.Lees Pharmaceutical is currently under evaluation in return on equity category among its peers.
Lees Fundamentals
Return On Equity | -0.0531 | |||
Return On Asset | 0.0591 | |||
Profit Margin | (0.09) % | |||
Operating Margin | (1.58) % | |||
Current Valuation | 123.64 M | |||
Shares Outstanding | 588.84 M | |||
Shares Owned By Insiders | 63.62 % | |||
Shares Owned By Institutions | 6.36 % | |||
Price To Book | 0.0002 X | |||
Price To Sales | 0.10 X | |||
Revenue | 1.27 B | |||
Gross Profit | 806.28 M | |||
EBITDA | 1.98 B | |||
Net Income | 1.99 B | |||
Cash And Equivalents | 368.05 M | |||
Cash Per Share | 0.62 X | |||
Total Debt | 84.09 M | |||
Debt To Equity | 0.11 % | |||
Current Ratio | 1.04 X | |||
Book Value Per Share | 3.64 X | |||
Cash Flow From Operations | 210.68 M | |||
Number Of Employees | 1.32 K | |||
Beta | 0.91 | |||
Market Capitalization | 275.66 B | |||
Total Asset | 3.64 B | |||
Annual Yield | 52.23 % | |||
Net Asset | 3.64 B | |||
Last Dividend Paid | 0.041 |
About Lees Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lees Pharmaceutical Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lees Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lees Pharmaceutical Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Lees Pink Sheet
If you are still planning to invest in Lees Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lees Pharmaceutical's history and understand the potential risks before investing.
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |